23.4 C
New York
Sunday, July 3, 2022

Ocugen Inc (OCGN) stock plunged in the pre-market. Here’s why

The stock of Ocugen Inc (OCGN) closed the recently traded session at $3.3, making no change from the previously traded session. On the last check, OCGN stock plunged in the pre-market and lost 10.61% to $2.95. The company declared the first clinical trials of the gene therapy platform. The company also declared the appointment of a new chief to its Board. Moreover, OCGN also filed forms 3, 4, and 8-K with the SEC on 23 March 2022.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



On 1 April 2022, OCGN reported that the principal patient has been dosed in the clinical preliminary of OCU400, a modifier quality treatment possible for the treatment of retinitis pigmentosa. This dosing marks the start of the portion raising, spectator blind, Phase 1/2 security, and viability study. RP is an intriguing, innate issue that includes a breakdown and loss of cells in the retina. As of now, there is no endorsed treatment planned to stop the movement of RP in light of the hereditary changes that cause the infection.

The CEO of OCGN, Dr. Shankar Musunuri, commented that everybody at Ocugen is amped up for this significant achievement. He further added that the primary period of the study is a security assessment of the item, in the end advancing into a viability study in patients.

Moreover, on 23 March 2022, OCGN pronounced the employment of Marna C. Whittington to its directorate. Her term became suitable on March 21, 2022. Dr. Whittington is an eminent pioneer in the financial area. She was the Chief Executive Officer of Allianz Global Investors Capital from 2001 until her retirement in January 2012. Dr. Whittington was a corporate official for Morgan Stanley Investment Management as well as the Finance Secretary for the State of Delaware. Dr. Whittington commented that this firm is making revelations through gallant advancement and situating itself to make huge commitments to the strength of communities. She further added that she liked the potential chance to add to proceeded progress of OCGN.


While stockholders extolled the advancement for OCU400, there hasn’t been a lot of reason recently to support Ocugen’s COVID-19 antibody, Covaxin. Ocugen anticipates an endorsement decision by Health Canada. Stockholders additionally are anxious for the organization to start its U.S. stage 2/3 review for Covaxin since the FDA lifted its clinical hold.

What does the analyst say?

ROTH Capital expressed in their examination note that they hope to see OCGN arrive at a value focus of $6, beforehand foreseeing the cost at $10. The rating they have accommodated OCGN stocks is “Neutral”.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles